Ads
related to: tegafur gimeracil oteracil potassium dose- Recommended Dosage
Discover Appropriate Dosage
to Treat Patients
- Kidney Transplant
Treatment for Kidney
Transplant Immunosuppression
- Storage & Handling
Learn to Properly Store and
Handle Treatment for Patients
- Kidney Transplant Therapy
Read About How Treatment May
Fight Against Acute Rejection
- Recipients
Discover How Patients
May Benefit from Treatment
- Medical Experts
Watch Healthcare Professionals
Share Transplant Insights
- Recommended Dosage
Search results
Results From The WOW.Com Content Network
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
The major side effects of tegafur are similar to fluorouracil and include myelosuppression, central neurotoxicity and gastrointestinal toxicity (especially diarrhoea). [3] Gastrointestinal toxicity is the dose-limiting side effect of tegafur. [3] Central neurotoxicity is more common with tegafur than with fluorouracil. [3]
This page was last edited on 8 September 2020, at 21:19 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The best time depends on your metformin type and dosage. Extended-release metformin tablets are usually taken once a day with your evening meal. Some people take metformin once, twice, or even ...
Tegafur/uracil (abbreviation: UFT [1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer. UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase ), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug ) in a 4:1 molar ratio.
Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. [1] [2] It is a CD19-directed genetically modified autologous T-cell immunotherapy.